22 results
Can this effect be utilised clinically, especially in patients with major depressive disorder?
Primary Objective:In this pilot study, the authors aim is to investigate whether esketamine reduces the incidence of POD in elderly patientspresenting for noncardiac surgery.Secondary Objective(s):To examine whether esketamine has an effect on the…
To evaluate the effect of intranasal esketamine 84 mg on cognition, and duration of cognitive effects (if present), as assessed using a computerized test battery (Cogstate®).
The aim of this study is to compare the integrity of the corticospinal tract and cortical reorganization of shoulder girdle muscle representations in chronic stroke patients with and without GHS as well as healthy controls.
We plan to (1) prove that microTMS can influence brain connectivity in healthy volunteers, and (2) optimize the stimulation parameters. As soon as a considerable effect is obtained, the new project will follow up for patients.
The goal of the current study is to investigate the functional relevance of higher order cortical areas for cognitive task execution involving inhibitory and emotional processes by means of TMS.
Primary objective: To demonstrate the superiority of QVA 110/50 µg compared to both QAB149 150 µg and NVA237 50 µg in terms of trough FEV1 (mean of 23 h 15 min and 23 h 45 min post-dose) following 26 weeks of treatment in patients with moderate to…
Primary objectiveTo evaluate the relationship of incremental doses of NVA237 q.d. and b.i.d. and their effect on trough FEV1 after 28 days of treatment, as defined by the percentage of the maximal effect that each dose achieves in relation to the…
Primary objectivesTo confirm that NVA237 50µg o.d. (delivered via a SDDPI) vs. placebo significantly increases trough FEV1 (defined as mean evaluation at 23 h 15 min and 23 h 45 min post dose) following 12 weeks of treatment in patients with…
Probleemstelling: Er is geen duidelijkheid of rTMS, toegepast binnen het reguliere revalidatieprogramma na een beroerte, leidt tot een extra verbetering in motorische herstel volgens de klinimetrie zoals gehanteerd binnen de in Nederland gebruikte…
Primary objective: To demonstrate that QVA149 (110/50 *g o.d.) is superior to NVA237 (50 *g o.d.) with regard to the rate of moderate to severe COPD exacerbations during 64 weeks of treatmentSecondary objectives: To demonstrate that QVA149 (110/50 *…
The primary objective is to investigate the influence of vigilance state on MEP amplitude in healthy adults. Secondary objectives are to develop a paradigm to stabilize vigilance state resulting in lower MEP amplitude variability in healthy adults…
Aims of the Study: Our main aim is to characterize cortical brain plasticity in individuals with impaired fasting glucose (IFG) and patients with type II diabetes mellitus (DM2) as compared with age-, gender-, and IQ-matched healthy controls(HC).•…
Primary ObjectiveTo evaluate the effect of a single 84-mg dose of intranasal esketamine compared to placebo, on next day driving performance and repeated administration of 84 mg intranasal esketamine on same-day driving performance as assessed by…
The aim of this study is to demonstrate that procedural sedation with propofol and esketamine is more effective and will result in less cardiopulmonary depression than sedation with propofol and the opioid alfentanil. Less side effects should also…
To explore whether influence on parasympathetic activity can be used as a functional outcome measure reflecting adequate targeting of the DLPFC-sgACC network and, secondary: 1) to explore the dose-response to the intensity of the TMS output and 2)…
Objective 1: To determine the effects of S-ketamine on brain activation in healthy women, healthy women prone to depression and fibromyalgia patients.Objective 2: To determine the effects of S-ketamine on mood and other depression-related behavioral…
The main objective of this study is to investigate whether rTMS add-on treatment will improve clinical outcomes in alcohol dependence. The secondary objective will be to answer the question through which mechanism rTMS will improve treatment…
The primary objective is to demonstrate non-inferiority of experimental esketamine administration of 6x 1 day per 2 weeks (in total 3 months) as compared with standard esketamine administration of 1x 6 consecutive days. The end of study is at 6…